{"title":"Faut-il revoir les indications des statines à la lumière des dernières données de la médecine fondée sur les preuves ?","authors":"M Farnier","doi":"10.1016/j.emcend.2004.03.002","DOIUrl":null,"url":null,"abstract":"<div><p>The studies HPS, LIPS, PROSPER, ALLHAT and ASCOT, on cardiovascular prevention, have made available relevant complementary information on statin utilisation. In patients with a history of vascular event, and in those under primary prevention and presenting with associated risk factors, the benefit of a statin treatment is indubitable, whatever the initial level of LDL-cholesterol. These studies provide also new evidence on beneficial results of statin therapy in diabetic patients, in women, and in elderly patients with high vascular risk. In the future, statin indication in any patient should depend primarily on the degree of his vascular risk. Such new issues of the evidence-based medicine should lead soon to re-actualised therapeutic recommendations.</p></div>","PeriodicalId":100422,"journal":{"name":"EMC - Endocrinologie","volume":"1 3","pages":"Pages 158-162"},"PeriodicalIF":0.0000,"publicationDate":"2004-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emcend.2004.03.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Endocrinologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762565304000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The studies HPS, LIPS, PROSPER, ALLHAT and ASCOT, on cardiovascular prevention, have made available relevant complementary information on statin utilisation. In patients with a history of vascular event, and in those under primary prevention and presenting with associated risk factors, the benefit of a statin treatment is indubitable, whatever the initial level of LDL-cholesterol. These studies provide also new evidence on beneficial results of statin therapy in diabetic patients, in women, and in elderly patients with high vascular risk. In the future, statin indication in any patient should depend primarily on the degree of his vascular risk. Such new issues of the evidence-based medicine should lead soon to re-actualised therapeutic recommendations.